Clinical Trials Browser

INDUSTRY × Liver Neoplasms × durvalumab × Clear all

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05063565 2026-03-02

ROWAN

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT06040099 2026-01-20

EMERALD-Y90

Phase 2 Active not recruiting

56 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03778957 2026-01-16

EMERALD-1

Phase 3 Active not recruiting

724 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05301842 2025-01-15

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

EMERALD-2

ROWAN

EMERALD-Y90

EMERALD-1

EMERALD-3

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.